Interferon-γ- and interleukin-4-targeted gene therapy for atopic allergic disease

K. W. Kang, Tae Sung Kim, Kyeong Man Kim

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Two cytokines, interferon-γ (IFN-γ) and interleukin-4 (IL-4), which play critical roles in the regulation of serum IgE level by directing the interplay of T helper (Th)1 and Th2 cells, were chosen as targets for gene therapy. Anti-allergic activity was evaluated by determining the serum IgE level, and the functional status of each helper T cell was monitored by the serum concentrations of IgG1 and IgG2a. Experimental animals (BALB/c mice) were divided into four groups: the control group; the ovalbumin (OVA) group; the IFN-γ group; and the IL-4 group. The control group was injected with saline and the OVA group with OVA-alum. The IFN-γ and IL-4 groups were treated with OVA-alum plus the cDNAs of mouse IFN-γ and IL-4 in an expression vector. These treatments were applied intramuscularly on a monthly basis for 4 months. OVA-alum treatment significantly increased the serum IgE and IgG1 concentrations, but did not affect IgG2a. Concomitant treatments with the cDNA of IFN-γ or IL-4 returned the serum IgE almost to the control level and significantly suppressed the OVA-induced increase of IgG1. IFN-γ cDNA increased the serum IgG2a but IL-4 cDNA had no affect. These results suggest that IFN-γ inhibited the OVA-induced IgE production by suppressing the Th2 pathway and by enhancing the Th1 pathway. Administration of IL-4 cDNA suppressed the OVA-induced enhancement of IgE production by inhibiting the Th2 pathway rather than by potentiating it.

Original languageEnglish
Pages (from-to)462-465
Number of pages4
JournalImmunology
Volume97
Issue number3
DOIs
Publication statusPublished - 1999 Jul 17
Externally publishedYes

Fingerprint

Interleukin-4
Genetic Therapy
Interferons
Immunoglobulin E
Ovalbumin
Complementary DNA
Serum
Immunoglobulin G
Anti-Allergic Agents
Th2 Cells
Control Groups
Th1 Cells
Helper-Inducer T-Lymphocytes
Therapeutics
Cytokines
ovalbumin-alum

ASJC Scopus subject areas

  • Immunology

Cite this

Interferon-γ- and interleukin-4-targeted gene therapy for atopic allergic disease. / Kang, K. W.; Kim, Tae Sung; Kim, Kyeong Man.

In: Immunology, Vol. 97, No. 3, 17.07.1999, p. 462-465.

Research output: Contribution to journalArticle

Kang, K. W. ; Kim, Tae Sung ; Kim, Kyeong Man. / Interferon-γ- and interleukin-4-targeted gene therapy for atopic allergic disease. In: Immunology. 1999 ; Vol. 97, No. 3. pp. 462-465.
@article{f80680b114f64f99a62c1eced369cd0b,
title = "Interferon-γ- and interleukin-4-targeted gene therapy for atopic allergic disease",
abstract = "Two cytokines, interferon-γ (IFN-γ) and interleukin-4 (IL-4), which play critical roles in the regulation of serum IgE level by directing the interplay of T helper (Th)1 and Th2 cells, were chosen as targets for gene therapy. Anti-allergic activity was evaluated by determining the serum IgE level, and the functional status of each helper T cell was monitored by the serum concentrations of IgG1 and IgG2a. Experimental animals (BALB/c mice) were divided into four groups: the control group; the ovalbumin (OVA) group; the IFN-γ group; and the IL-4 group. The control group was injected with saline and the OVA group with OVA-alum. The IFN-γ and IL-4 groups were treated with OVA-alum plus the cDNAs of mouse IFN-γ and IL-4 in an expression vector. These treatments were applied intramuscularly on a monthly basis for 4 months. OVA-alum treatment significantly increased the serum IgE and IgG1 concentrations, but did not affect IgG2a. Concomitant treatments with the cDNA of IFN-γ or IL-4 returned the serum IgE almost to the control level and significantly suppressed the OVA-induced increase of IgG1. IFN-γ cDNA increased the serum IgG2a but IL-4 cDNA had no affect. These results suggest that IFN-γ inhibited the OVA-induced IgE production by suppressing the Th2 pathway and by enhancing the Th1 pathway. Administration of IL-4 cDNA suppressed the OVA-induced enhancement of IgE production by inhibiting the Th2 pathway rather than by potentiating it.",
author = "Kang, {K. W.} and Kim, {Tae Sung} and Kim, {Kyeong Man}",
year = "1999",
month = "7",
day = "17",
doi = "10.1046/j.1365-2567.1999.00802.x",
language = "English",
volume = "97",
pages = "462--465",
journal = "Immunology",
issn = "0019-2805",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Interferon-γ- and interleukin-4-targeted gene therapy for atopic allergic disease

AU - Kang, K. W.

AU - Kim, Tae Sung

AU - Kim, Kyeong Man

PY - 1999/7/17

Y1 - 1999/7/17

N2 - Two cytokines, interferon-γ (IFN-γ) and interleukin-4 (IL-4), which play critical roles in the regulation of serum IgE level by directing the interplay of T helper (Th)1 and Th2 cells, were chosen as targets for gene therapy. Anti-allergic activity was evaluated by determining the serum IgE level, and the functional status of each helper T cell was monitored by the serum concentrations of IgG1 and IgG2a. Experimental animals (BALB/c mice) were divided into four groups: the control group; the ovalbumin (OVA) group; the IFN-γ group; and the IL-4 group. The control group was injected with saline and the OVA group with OVA-alum. The IFN-γ and IL-4 groups were treated with OVA-alum plus the cDNAs of mouse IFN-γ and IL-4 in an expression vector. These treatments were applied intramuscularly on a monthly basis for 4 months. OVA-alum treatment significantly increased the serum IgE and IgG1 concentrations, but did not affect IgG2a. Concomitant treatments with the cDNA of IFN-γ or IL-4 returned the serum IgE almost to the control level and significantly suppressed the OVA-induced increase of IgG1. IFN-γ cDNA increased the serum IgG2a but IL-4 cDNA had no affect. These results suggest that IFN-γ inhibited the OVA-induced IgE production by suppressing the Th2 pathway and by enhancing the Th1 pathway. Administration of IL-4 cDNA suppressed the OVA-induced enhancement of IgE production by inhibiting the Th2 pathway rather than by potentiating it.

AB - Two cytokines, interferon-γ (IFN-γ) and interleukin-4 (IL-4), which play critical roles in the regulation of serum IgE level by directing the interplay of T helper (Th)1 and Th2 cells, were chosen as targets for gene therapy. Anti-allergic activity was evaluated by determining the serum IgE level, and the functional status of each helper T cell was monitored by the serum concentrations of IgG1 and IgG2a. Experimental animals (BALB/c mice) were divided into four groups: the control group; the ovalbumin (OVA) group; the IFN-γ group; and the IL-4 group. The control group was injected with saline and the OVA group with OVA-alum. The IFN-γ and IL-4 groups were treated with OVA-alum plus the cDNAs of mouse IFN-γ and IL-4 in an expression vector. These treatments were applied intramuscularly on a monthly basis for 4 months. OVA-alum treatment significantly increased the serum IgE and IgG1 concentrations, but did not affect IgG2a. Concomitant treatments with the cDNA of IFN-γ or IL-4 returned the serum IgE almost to the control level and significantly suppressed the OVA-induced increase of IgG1. IFN-γ cDNA increased the serum IgG2a but IL-4 cDNA had no affect. These results suggest that IFN-γ inhibited the OVA-induced IgE production by suppressing the Th2 pathway and by enhancing the Th1 pathway. Administration of IL-4 cDNA suppressed the OVA-induced enhancement of IgE production by inhibiting the Th2 pathway rather than by potentiating it.

UR - http://www.scopus.com/inward/record.url?scp=0033008171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033008171&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2567.1999.00802.x

DO - 10.1046/j.1365-2567.1999.00802.x

M3 - Article

VL - 97

SP - 462

EP - 465

JO - Immunology

JF - Immunology

SN - 0019-2805

IS - 3

ER -